Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib/II Study of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Patients with Untreated Metastatic Pancreatic Adenocarcinoma

Summary

The purpose of this phase Ib/II trial is to evaluate the safety and feasibility of modified FOLFIRINOX combined with IV infusions of ABB-927 with or without Budigalimab (ABBV-181) in patients with untreated metastatic pancreatic cancer.

General Information

NCT#: NCT04807972
Study ID: M20-732
Trial Phase: Phase II

Trial Sponsor: AbbVie
Therapies Used in This Trial: FOLFIRINOX, ABBV-927, Budigalimab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search